The observed mutations of genes involved in antitumor immune responses were mostly polyclonal, but mutations in CSMD1, MUC16 and TTN occurred as clonal alterations, suggesting again a clonal advantage for those tumor cells (Table 5 and Supplementary Table S1). This evidence concerns the gene MUC16 and neoplasm.